Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 25, 2017 - Issue 3
Submit an article Journal homepage
794
Views
39
CrossRef citations to date
0
Altmetric
Articles

Adalimumab for Ocular Inflammation

Khayyam DurraniMassachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA;Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USAView further author information
, MD,
John H. KempenCenter for Preventive Ophthalmology and Biostatistics;Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAView further author information
, MD, PhD,
Gui-shuang YingCenter for Preventive Ophthalmology and BiostatisticsView further author information
, PhD,
R. Oktay KacmazMassachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USAView further author information
, MD, MPH,
Pichaporn ArtornsombudhMassachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA;Center for Preventive Ophthalmology and BiostatisticsView further author information
, MD,
James T. RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA;Department of Medicine, Oregon Health and Science University, Portland, Oregon, USAView further author information
, MD,
Eric B. SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA;Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA;Portland Veteran’s Affairs Medical Center, Portland, Oregon, USAView further author information
, MD, MPH,
Jennifer E. ThorneDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USAView further author information
, MD, PhD,
Douglas A. JabsJohns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA;Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, USA;Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USAView further author information
, MD, MBA,
Grace A. Levy-ClarkeLaboratory of Immunology, National Eye Institute, Bethesda, Maryland, USAView further author information
, MD,
Robert B. NussenblattLaboratory of Immunology, National Eye Institute, Bethesda, Maryland, USAView further author information
, MD, MPH,
C. Stephen Foster md, facsMassachusetts Eye Research & Surgery Institution and Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA;Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USACorrespondence[email protected]
View further author information
&
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research GroupView further author information
 show all
Pages 405-412 | Received 17 Feb 2015, Accepted 16 Dec 2015, Published online: 22 Mar 2016

REFERENCES

  • Yoshida M, Yoshimura N, Hangai M, et al. Interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1994;35:1107–1113.
  • Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008;8:339–347.
  • Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
  • Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121–136.
  • Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
  • Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–361.
  • Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696–701.
  • Winterhalter S, Niehues T. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? An evidence based approach. Klin Padiatr. 2008;220:342–347.
  • van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behcet’s disease? Ann Rheum Dis. 2007;66:565–566.
  • Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, et al. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25:596–597.
  • Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol. 2005;32:1374–1375.
  • Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–79.
  • Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486.
  • Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63:612–618.
  • Sen ES, Sharma S, Hinchcliffe A, et al. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease – a case cohort interventional study. Rheumatology (Oxford). 2012;51:2199–2203.
  • Martel JN, Esterberg E, Nagpal A, et al. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20:18–26.
  • Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429.
  • Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–138.
  • Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
  • Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol. 2005;139:900–905.
  • Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15:47–55.
  • Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–2198.
  • Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339–344.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.